HomepageHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Vorige slotkoers
€ 25,85
Dag-range
€ 25,67 - € 25,67
Jaar-range
€ 19,52 - € 36,69
Beurswaarde
3,58 mld. USD
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | — | — |
Bedrijfskosten | 126,19 mln. | 28,63% |
Netto inkomsten | -125,30 mln. | -357,42% |
Netto winstmarge | — | — |
Winst per aandeel | -1,02 | -326,67% |
EBITDA | -121,67 mln. | -339,34% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 520,91 mln. | 8,30% |
Totale activa | 955,15 mln. | 7,16% |
Totale passiva | 459,74 mln. | 7,87% |
Totaal aandelenvermogen | 495,40 mln. | — |
Uitstaande aandelen | 124,20 mln. | — |
Koers-boekwaardeverhouding | 6,63 | — |
Rendement op activa | -39,90% | — |
Rendement op kapitaal | -43,18% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -125,30 mln. | -357,42% |
Operationele kasstroom | -92,38 mln. | -191,68% |
Kasstroom uit beleggingen | -268,94 mln. | -645,70% |
Kasstroom uit financiering | 430,78 mln. | 82.741,73% |
Nettomutatie in liquide middelen | 69,49 mln. | 203,27% |
Vrije kasstroom | -91,82 mln. | -262,49% |
Over
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Opgericht
1 jan 2004
Hoofdvestiging
Website
Werknemers
525